Enlivex Ltd. · NASDAQ:ENLV
Enlivex — Investor Presentation (June 2026)
25 slides from Enlivex's investor presentation, Jun 24, 2026
Slide 1: The Quality Longevity Company Powered by a Prediction Markets Treasury
The Quality Longevity Company Powered by a Prediction Markets Treasury
Slide 2: Forward-looking statements
Forward-looking statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements may be identified by words such as “expec
Slide 3: Enlivex: The World's First Healthspan-Wealthspan Company
Enlivex: The World's First Healthspan-Wealthspan Company Primary Engine Secondary Engine Quality Longevity Through Potential Medical Prediction Markets Treasury Breakthroughs ● Advanced Clinical-stage Allocetra ● Largest institutional holder of RAIN, the governance immunotherapy currently targeting
Slide 4: The Dual Engine Architecture
Executive Summary The Capital Structure Innovation: Enlivex is pioneering a hybrid The Dual Engine Architecture institutional model, utilizing a digital asset treasury designed to fuel breakthrough quality longevity therapeutics. The Quality Longevity Therapeutics: Allocetra targets primarily age- r
Slide 5: How Capital Velocity Potentially Accelerates Longevity Breakthroughs
How Capital Velocity Potentially Accelerates Longevity Breakthroughs The Traditional Model: Clinical development funding through frequent equity raises that progressively dilute shareholders. The Enlivex Architecture: Wealthspan Velocity: Prediction markets treasury generates non- dilutive capital t
Slide 6: Prediction Markets: How Distributed Intelligence Prices the Future
Prediction Markets: How Distributed Intelligence Prices the Future A prediction market is a trading platform where contract value is determined entirely by the outcome of future events. Participants buy and sell outcome-specific positions, putting real capital behind their convictions. The result: a
Slide 7: The Institutional Transition Is Already Underway
The Institutional Transition Is Already Underway $2BN investment ($8BN Valuation) by Kalshi's $1BN financing ($22BN Valuation) Intercontinental Exchange (ICE), the with Coatue Management, following parent company of New York Stock previous financing round led by Paradigm, Exchange (NYSE) in Polymark
Slide 8: RAIN is the leading prediction market and options protocol on Arbitrum
RAIN is the leading prediction market and options protocol on Arbitrum. Core Architecture: ● Permissionless Market Creation: Anyone, anywhere, any language. No approval. ● Hybrid AI-Human Oracle: OlympusAI resolves outcomes with human validation. ● Full Builder Infrastructure: Complete API/SDK enabl
Slide 9: Prediction Markets League Table
Prediction Markets League Table Rank, liquidity #1, ~$450MM #2, ~$250MM #3, ~$100MM Language English English Any Language Market Creation Disabled Disabled Anyone can Create Trading date, Trading Trading date, Trading End to end platform Builder’s Capabilities Automation Automation capabilities Mark
Slide 10: The 5% Protocol Fee and the Mechanistic Deflationary Engine
The 5% Protocol Fee and the Mechanistic Deflationary Engine 2.5% — Participation Rewards Distributed to market participants to ensure deep, self-sustaining liquidity: ● 1.2% to Market Creators ● 1.2% to Liquidity Providers ● 0.1% to Resolvers 2.5% — Buyback & Burn The protocol automatically acquires
Slide 11: RAIN Buyback & Burn Forecast
RAIN Buyback & Burn Forecast $2.5B in Cumulative Supply Reduction by 2030 Prediction Markets Forecast: ● $1 trillion trading volume by 20301 ● RAIN market shares estimated to be 5%2 Period Buyback & Burn Volume 2026–2029 (Aggregate) $1.25 Billion 2030 (Annual) $1.25 Billion Through 2030 (Total) $2.2
Slide 12: Rain Ecosystem Expansion Expected Roadmap
Rain Ecosystem Expansion Expected Roadmap Provided By The Rain Foundation Completed Coming next Public API & SDK Release (Protocol V1) Grants Program for Builders Builder Program Launch 50+ Builder Ecosystem Apps Rain DAO Launch Ongoing Shared Liquidity Protocol Fixed-Payout & New Market Maker Model
Slide 13: Expanding market accessibility and liquidity depth for RAIN
Expanding market accessibility and liquidity depth for RAIN Current Listings: Structural Impact: ● Reduced slippage for institutional-scale trades ● Enhanced price discovery through deeper order books ● 24/7 global trading depth enabling algorithmic strategies 13
Slide 14: Leveraging the economic accelerator
Leveraging the economic accelerator Enlivex is currently the largest corporate holder of RAIN. Enlivex instructed its RAIN asset manager, at its discretion, to utilize yield- enhancement activities, which potentially could result in outperformance of the spot token. Potential active yield-enhancemen
Slide 15: Portfolio Update
Portfolio Update As of May 28, 2026 • The market value of the Company's digital asset treasury was approximately $1 billion • Treasury-related derivative instrument (option to acquire RAIN) value: $2.6 Billion The updated unaudited mark-to-market treasury metrics are publicly available on the Compan
Slide 16: Quality Longevity Therapeutics
Quality Longevity Therapeutics 16
Slide 17: Osteoarthritis: The #1 debilitating disease
Osteoarthritis: The #1 debilitating disease Disease Overview Market Standard of Care Lifestyle Changes Physiotherapy Pain Medication Disease Manifestation: Cartilage Surgery damage, abnormal bone remodeling and inflammation of the synovium. 1 - Arthritis Fou ndation (http s://www.arthritis.o rg/) 2
Slide 18: Knee osteoarthritis: Increased risk of mortality and reduced quality of longevity
KNEE OSTEOARTHRITIS: Increased risk of mortality and reduced quality of longevity The most comprehensive and recent meta-analysis (2024), covering over one million participants, found that knee OA patients had a 21% higher risk of all-cause mortality compared to those without knee OA 1. Knee OA incr
Slide 19: Allocetra: An off-the-shelf cell therapy designed to restore macrophage homeostasis
AllocetraTM: An off-the-shelf cell therapy designed to restore macrophage homeostasis Process: PtdSer Eat Me Apoptotic Cell AllocetraTM Collect cells from healthy donors Proprietary apoptotic cell modification process Cells express 'eat me' signal Cells are frozen Off the shelf, c ost effective cell
Slide 20: ENX-CL-05-001: Phase I/IIa
ENX-CL-05-001: PHASE I/lla 2-stage trial design - randomized, double-blind, placebo-controlled, multi-country study Phase I: Dose escalation & safety Patient Criteria 15 patients ● Patients with Independent safety committee→ no negative safety signal, highest dose selected for Phase lla symptomatic
Slide 21: Trending with age
ENX-CL-05-001 results: Clinically meaningful, statistically significant positive effect, highly correlated with primary OA age threshold The positive effect of AllocetraTM on pain & function is substantial, with at least 6-month durability. Change from baseline - 3 months Change from baseline - 6 mo
Slide 22: ENX-CL-05-002, a Phase IIb in primary age-related KOA patients
ENX-CL-05-002, a PHASE IIb in primary age-related KOA patients Randomized, double-blind, placebo-controlled, multi-country study First Patient dosed in US Phase IIb: Randomized, double-blind, placebo-controlled AllocetraTM (1 or 2 doses) vs. Placebo , 3 injections in total, each injection 2 weeks fr
Slide 23: The Quality Longevity Opportunity
The Quality Longevity Opportunity Management team with a track record of creating shareholder value and getting drug products through marketing approvals globally in multi-billion dollar market segments. Cost-effective, novel therapeutic modality with strong IP protection. Targeted at high and low g
Slide 24: Enlivex Quality Longevity Team
Enlivex Quality Longevity Team Shai Novik Oren Hershkovitz, Ph.D. Prof. Dror Mevorach, M.D. Executive Chairman Chief Executive Officer Co-Founder & Scientific Adviser Shai Novik is Co-Founder and Executive Dr. Oren Hershkovitz, CEO of Enlivex since 2019, is a Prof. Dror Mevorach, co-founder of Enliv
Slide 25: Where prediction markets fund longevity breakthroughs.
Where prediction markets fund longevity breakthroughs. shachar@enlivex.com www.enlivex.com